⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810498 | 0.91 | — | — | |
| SCHEMBL1807609 | 0.91 | — | — | |
| SCHEMBL1809325 | 0.73 | — | — | |
| SCHEMBL1894280 | 0.73 | — | — | |
| SCHEMBL7109 | 0.73 | — | — | |
| SCHEMBL27078 | 0.72 | — | — | |
| SCHEMBL13101792 | 0.69 | — | — | |
| SCHEMBL31122211 | 0.69 | ALDH1A1 (0.39) | — | |
| SCHEMBL31586669 | 0.67 | — | — | |
| SCHEMBL487224 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-11510888-B2 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-RE49238-E1 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2701698-B1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012148930-A2 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148927-A2 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148929-A2 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148926-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2493296-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | Retrotope, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110105609-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | RETROTOPE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105609-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | RETROTOPE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2011053870-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | RETROTOPE, INC. (US) | 2011-05-05 | — | — | WO | disclosed |